Author: [email protected]

Eledon Pharmaceuticals Reports Positive Kidney Transplant Trial Data as Tegoprubart Improves Quality of Life

Posted on by [email protected]

Eledon Pharmaceuticals (NASDAQ: ELDN) announced new positive Phase 2 clinical trial results Monday showing that its investigational kidney transplant therapy, tegoprubart, delivered sustained improvements in patient-reported quality of life and transplant-related symptoms compared with tacrolimus, a commonly used immunosuppressive treatment.

The findings, presented at the American Society of Nephrology’s Kidney Week 2026 meeting in Denver, add to previously reported results from Eledon’s Phase 2 BESTOW trial and highlight the potential for a new approach to managing immune suppression following kidney transplantation.

Kidney transplant recipients typically require lifelong immunosuppressive medications to prevent their immune systems from rejecting donated organs. Although existing treatments have significantly improved transplant outcomes, they can produce side effects that affect patients’ daily lives and long-term health.

Eledon’s tegoprubart is designed to address this challenge by targeting CD40 ligand, a protein involved in activating immune responses. Unlike traditional immunosuppressive therapies, the investigational antibody aims to regulate immune activity through a different biological pathway.

The latest BESTOW findings focused on patient-reported outcomes, including physical symptoms, emotional well-being, and overall quality of life during the first year following transplantation.

Researchers evaluated patients using two established assessment tools: the Modified Transplant Symptom Occurrence and Symptom Distress Scale and the Kidney Disease Quality of Life Short Form.

At 12 months, patients receiving tegoprubart demonstrated continued improvements in overall symptom occurrence, while patients treated with tacrolimus experienced a slight worsening compared with their baseline measurements.

Tegoprubart also showed greater symptom improvement in 22 of 23 categories where differences between the treatment groups were observed. These included neurological, gastrointestinal, metabolic, and physical symptoms.

One of the most notable findings involved the Kidney Disease Quality of Life assessment. Patients receiving tegoprubart reported an average nine-point improvement on the Symptoms and Problems Scale, compared with a 3.3-point improvement among patients receiving tacrolimus.

The difference was statistically significant, with Eledon noting that a change of three to five points on the scale can be considered clinically meaningful.

Additional findings suggested potential benefits for mental well-being. Patients treated with tegoprubart experienced a 1.5-point improvement in the mental component summary score, compared with a 1.6-point decline in the tacrolimus group.

The findings suggest that tegoprubart’s potential benefits may extend beyond preventing organ rejection to improving how transplant recipients feel and function in everyday life.

For Eledon, the results provide additional evidence supporting the differentiated clinical profile of its lead drug candidate. Previous BESTOW findings addressed measures of efficacy, kidney function, and safety, while the newly presented data provide further insight into the patient experience.

The development is relevant to investors because kidney transplantation represents a specialized therapeutic market in which effective treatments that reduce medication-related complications could address an important unmet medical need.

However, tegoprubart remains investigational and has not received regulatory approval. Additional clinical development and regulatory review will be necessary before its potential commercial use can be established.

Eledon is also exploring the broader applications of its anti-CD40L technology across other transplantation settings and immune-related conditions, including islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis.

The latest results underscore growing interest in developing more targeted immunosuppressive treatments that balance the prevention of organ rejection with patients’ long-term quality of life.

For small-cap biotechnology investors, Eledon’s findings represent another clinical development milestone as the company works to advance tegoprubart and demonstrate its potential as an alternative to existing kidney transplant therapies.

Take a moment to read more equity research on Eledon Pharmaceuticals here.

Cosmos Health (COSM) – Building a Higher-Margin Healthcare Platform

Posted on by [email protected]


Monday, October 26, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating. We believe Cosmos Health is positioned for a meaningful improvement in profitability as its revenue mix shifts toward higher-margin proprietary healthcare products and pharmaceutical manufacturing. The company’s established wholesale distribution business provides a revenue base, while its expanding U.S. direct-to-consumer operations could become an increasingly important driver of earnings growth.

U.S. direct-to-consumer sales are gaining momentum. Management expects approximately $15 million in fourth-quarter 2026 U.S. e-commerce revenue and $10.5 million in gross profit, reflecting the rapid expansion of its proprietary nutraceutical business. Active U.S. subscriptions reached 8,940 as of October 19, although customer retention and marketing efficiency remain important considerations as the business scales.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Roche Signs $813 Million Zymeworks Cancer Drug Deal as Biotech Partnerships Accelerate

Posted on by [email protected]

Roche is expanding its oncology pipeline through a licensing agreement with Zymeworks (NASDAQ: ZYME) valued at up to $813 million, highlighting continued interest from major pharmaceutical companies in experimental cancer treatments developed by smaller biotechnology firms.

The agreement, announced October 23, 2026, gives Swiss pharmaceutical giant Roche exclusive worldwide rights to develop and commercialize ZW209, an investigational therapy designed to treat certain cancers, including small-cell lung cancer.

Under the agreement, Zymeworks will receive an upfront payment of $55 million, followed by an additional $40 million if Roche initiates a planned Phase 1b clinical trial. The biotechnology company could also receive up to $718 million in development, commercial, and sales-related milestone payments, along with royalties on future sales of approved treatments.

The full $813 million value is contingent on achieving specified milestones and does not represent guaranteed revenue.

ZW209 belongs to an emerging class of cancer therapies known as trispecific T-cell engagers. These treatments are designed to help the immune system recognize and attack cancer cells by connecting immune cells with specific targets found on tumors.

The experimental drug targets DLL3, a protein frequently expressed in small-cell lung cancer and certain other neuroendocrine tumors but generally found at low levels in healthy tissue.

ZW209 is designed to engage DLL3 while simultaneously interacting with two proteins on immune cells, CD3 and CD28. This approach aims to stimulate an immune response against cancer cells while potentially improving the effectiveness and durability of treatment.

The drug remains in early clinical development, and its safety and effectiveness in patients have not yet been established.

Zymeworks will conduct the Phase 1a portion of the clinical program in collaboration with Roche, which will fund the study. Roche will subsequently assume responsibility for global development and commercialization.

The first patient is expected to enter the study before the end of 2026, according to Zymeworks management.

For investors, the transaction illustrates an important strategy in the biotechnology industry: smaller drug developers can use licensing agreements to secure funding and share clinical development risks while retaining opportunities for future milestone payments and royalties.

These partnerships can be particularly valuable for emerging biotechnology companies, where clinical trials require substantial investment and successful commercialization often depends on extensive manufacturing, regulatory, and distribution capabilities.

Roche’s decision to partner on ZW209 before human efficacy data are available also underscores the importance pharmaceutical companies place on differentiated scientific platforms and promising early-stage research.

The agreement reflects broader interest in innovative oncology treatments, including immunotherapies and therapies designed to target specific biological mechanisms involved in cancer.

Within Noble Capital Markets’ research coverage universe, Greenwich LifeSciences (NASDAQ: GLSI) is developing an investigational immunotherapy for breast cancer, while Cardiff Oncology (NASDAQ: CRDF) is advancing onvansertib, an experimental cancer treatment targeting the PLK1 enzyme. Although their technologies differ from ZW209, these companies illustrate the range of oncology approaches being pursued by emerging biotechnology developers. Neither company is involved in the Roche-Zymeworks agreement.

The transaction also highlights the potential financial importance of early-stage biotechnology partnerships. Rather than acquiring entire companies, larger pharmaceutical businesses can license individual drug candidates, gaining access to promising technologies while limiting their initial financial commitments.

However, significant risks remain. Experimental cancer treatments face lengthy clinical trials, regulatory scrutiny, and uncertainty surrounding patient outcomes. Milestone payments depend on future progress, and many investigational therapies never reach commercialization.

The Roche-Zymeworks agreement remains subject to customary closing conditions, including applicable antitrust clearance.

For small-cap biotechnology investors, the deal provides another example of how innovative drug-development platforms can attract major pharmaceutical partners. As competition for differentiated cancer treatments continues, licensing agreements may remain an important source of funding and strategic validation for emerging biotech companies.

Release – Conduent Completes $447 Million Refinancing, Advancing Deleveraging and De-Risking

Posted on by [email protected]

October 23, 2026

Conduent Incorporated (Nasdaq: CNDT) (“Conduent” or the “Company”), a global technology-enabled operating partner, today announced the successful closing of a comprehensive $447 million refinancing transaction. The transaction extends the Company’s $357 million revolving credit facility through May 2029 and adds $90 million in additional commitments from its existing bank lenders, including a $15 million letter of credit facility, reflecting confidence in the Company’s strategy. Together with the Company’s recent and announced divestitures, including the use of proceeds to repay debt, these actions advance Conduent’s strategy to delever and de-risk its business and create greater flexibility to execute ASCEND 2026–28, the Company’s strategic plan outlined at its recent Investor Day.

The transaction establishes new revolving credit facilities with a group of existing bank lenders and rolls certain commitments under the existing revolver into the new facilities, extending maturities from October 2026 and May 2028 to May 2029.

The transaction builds on Conduent’s recently completed sale of its Public Transit business and the announced sale of its Tolling business. Together, these portfolio actions and the refinancing are expected to reduce the Company’s surety bond and letter-of-credit portfolio by approximately $550 million upon completion of the announced Tolling sale, significantly reducing financial encumbrances and releasing capital currently supporting those instruments.

With maturities extended to 2029, Conduent can continue investing in its core businesses and executing ASCEND 2026–28, the Company’s plan to accelerate profitable growth by standardizing its operations, specializing in the core solutions where it can lead and win, and scaling its go-to-market capabilities. The Company’s government and commercial programs, which millions of people rely on every day, continue without interruption.

“Deleveraging and de-risking are important priorities as we advance ASCEND 2026–28. We’ve extended our maturities, secured additional commitments from our banking partners and used divestiture proceeds to repay debt. Together with a meaningful reduction in our surety bond and letter-of-credit requirements, these actions strengthen our financial foundation and give us greater flexibility to invest in our core businesses and execute our strategy. They also support our mission to be the premier AI-led and technology-enabled business process partner for Government and Commercial clients, helping them modernize operations, enhance customer and constituent experiences, and achieve measurable business outcomes. Our banking partners’ commitment of new capital reflects their confidence in our strategy and our ability to execute ASCEND 2026–28,” said Harsha V. Agadi, Conduent President and Chief Executive Officer.

Lazard served as strategic advisor to Conduent.

About Conduent
Conduent is a global technology-enabled operating partner that helps businesses and governments simplify complexity, modernize mission-critical operations and deliver measurable outcomes through AI, automation, data and human expertise. Learn more at www.conduent.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “estimate,” “expect,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue to,” “endeavor,” “if,” “growing,” “projected,” “potential,” “likely,” “see,” “ahead,” “further,” “going forward,” “on the horizon,” and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements include, but may not be limited to, statements regarding the Company’s Public Transit and Tolling business sales and our ability to meet the requirements and obligations under the new revolving credit facilities entered into in connection with the Transaction. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make. Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to: our significant indebtedness and the terms of such indebtedness; our ability to refinance, extend or replace our indebtedness on acceptable terms or at all; our failure to obtain or maintain a satisfactory credit rating and financial performance; and other factors that are set forth in the “Risk Factors” and other sections of our Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this press release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks
Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contact:
Remy Kaul, Conduent, [email protected]

Investor Relations Contact:
Nick Goel, Conduent, [email protected]

Release – ACCO Brands Corporation Declares Quarterly Dividend

Posted on by [email protected]

Company's logo

10/23/2026

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its board of directors has declared a quarterly cash dividend of $0.075 per share. The dividend will be paid on December 9, 2026, to stockholders of record as of the close of business on November 20, 2026.

About ACCO Brands Corporation
ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

Chris McGinnis
Investor Relations
(847) 796-4320

Kori Reed
Media Relations
(224) 501-0406

Source: ACCO Brands Corporation

Multimedia Files:

Small-Cap Stocks Outperform as Russell 2000 Gains 2.3% While Nasdaq Slides

Posted on by [email protected]

Small-cap stocks are showing renewed strength on Wall Street as investors shift attention away from large technology companies amid growing concerns about artificial intelligence spending, elevated valuations, and interest rates. The Russell 2000 index, which tracks approximately 2,000 smaller publicly traded U.S. companies, has gained 2.3% this week through Thursday, outperforming the Nasdaq Composite and S&P 500.

The divergence became particularly noticeable during Thursday’s trading session, when the Nasdaq plunged 2.6% as technology stocks faced renewed selling pressure. Meanwhile, the Russell 2000 managed a modest 0.1% gain, suggesting investors were finding opportunities outside the technology sector despite broader market uncertainty.

The S&P 500 declined 1.2% Thursday, its steepest daily loss since July, while the Dow Jones Industrial Average finished essentially unchanged. The Russell 2000 closed at 2,784.03, compared with the Nasdaq’s closing level of 26,008.86.

For the week through October 22, the Russell 2000 advanced 2.3%, while the Nasdaq declined 0.5%. The Dow gained 1.7%, and the S&P 500 remained nearly flat.

The performance gap highlights a potential shift in investor sentiment after an extended period in which large technology companies dominated stock market returns.

Artificial intelligence has been a major driver of equity market enthusiasm, particularly among companies developing advanced computing infrastructure, semiconductors, and AI-powered software. However, investors are increasingly examining whether the enormous spending required to build and operate AI systems can generate sufficient financial returns.

Concerns about capital expenditures, borrowing costs, and profitability have contributed to volatility in technology shares, creating opportunities for other sectors to attract investor attention.

Small-cap stocks have historically been sensitive to changes in interest rates because smaller businesses often depend more heavily on external financing. Lower borrowing costs can support expansion, acquisitions, and investment, although the benefits vary considerably across industries and individual companies.

Recent declines in Treasury yields could provide some relief for smaller businesses, but the Federal Reserve’s monetary policy outlook remains uncertain as inflation pressures persist.

Beyond interest rates, investors are also reconsidering valuations. Following substantial gains among leading technology companies, smaller stocks in sectors such as industrials, financial services, transportation, and healthcare may offer different growth opportunities and risk profiles.

Thursday’s market action demonstrated that distinction. Although the major technology-heavy indexes declined, advancing stocks outnumbered declining stocks across the broader market, suggesting the selling was concentrated rather than universal.

For investors focused on emerging companies, this broader participation could be significant. Small-cap businesses often receive less analyst coverage and institutional attention than their large-cap counterparts, creating opportunities for investors willing to evaluate individual companies and industry fundamentals.

However, the Russell 2000’s recent strength does not necessarily signal the beginning of a sustained small-cap rally. Smaller companies remain exposed to economic uncertainty, financing constraints, and changes in consumer and business spending.

A prolonged rotation would likely depend on several factors, including corporate earnings growth, inflation trends, interest-rate expectations, and continued investor demand beyond the largest technology stocks.

For now, the Russell 2000’s relative strength provides an important signal about changing market dynamics. As investors reassess the valuations and spending commitments of major AI companies, smaller publicly traded businesses are attracting renewed attention.

Whether that interest develops into a longer-term trend will depend on the ability of small-cap companies to deliver earnings growth and demonstrate resilience in a challenging economic environment.

Seanergy Maritime (SHIP) – Raising Estimates, Fleet Growth Ahead

Posted on by [email protected]


Friday, October 23, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Increasing third-quarter estimates. We have increased our third-quarter revenue, adj. EBITDA, and adj. EPS estimates to $55.4 million, $35.0 million, and $0.95, respectively, from $53.4 million, $32.0 million, and $0.86. Our revised estimates reflect a higher average time charter equivalent (TCE) rate of $32,750 per day. Moreover, we have increased our FY 2026 revenue, adj. EBITDA and adj. EPS estimates to $209.4 million, $139.7 million, and $3.85, respectively, from $205.9 million, $134.2 million, and $3.70.

Looking ahead. We expect Seanergy’s fleet renewal program to support earnings growth in 2027, with four newbuild vessels scheduled for delivery during the year. These additions should enhance revenue growth, improve operating efficiency, and reduce average vessel age. We also anticipate selective disposals of older vessels, partially offsetting fleet growth while advancing the company’s modernization strategy. While dry dockings, delivery timing, and freight-rate volatility could affect 2027 results, we expect the new vessels to contribute more meaningfully to earnings and cash flow in 2028.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kodiak Copper Corp. (KDKCF) – Kodiak Advances MPD Metallurgy Ahead of Key 2027 Catalysts

Posted on by [email protected]


Friday, October 23, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Metallurgical work begins. Kodiak Copper has commenced an additional metallurgical program at its 100%-owned MPD copper-gold porphyry project in southern British Columbia. The new work builds on positive results reported earlier this year and is focused on flowsheet development and optimization. The program is intended to improve the technical foundation for future economic studies while MPD continues to advance through ongoing exploration and resource growth.

Project-wide testing. The program is broad in scope and will include representative material from all seven deposits included in MPD’s mineral resource estimate: 1) Gate, 2) Ketchan, 3) Man, 4) Dillard, 5) West, 6) Adit, and 7) South. Four composite samples representing the Southern Area, Northern Area, Ketchan, and Gate will undergo mineralogical, comminution, gravity, flotation, locked cycle, and concentrate quality testing. In our view, this should help determine whether a common processing flowsheet can be applied across multiple deposits, which could simplify future development and provide greater flexibility in mine planning and deposit sequencing.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Oil Prices Surge Above $110 as U.S.-Iran Tensions Raise Fears of Escalation After Midterms

Posted on by [email protected]

Oil prices surged Thursday as investors weighed reports that the United States and Israel could intensify military operations against Iran following the November midterm elections, raising concerns about additional disruptions to global energy supplies and renewed inflationary pressure.

Brent crude futures climbed above $111 per barrel during early trading on October 22, approaching a five-month high, while U.S. West Texas Intermediate crude rose toward $100. The gains reflected growing uncertainty surrounding the Middle East conflict and the potential consequences for oil production, shipping routes, and global economic growth.

According to reports citing The New York Times, U.S. and Israeli officials have been considering expanded military operations targeting Iranian energy infrastructure and other strategic facilities after the November 3 elections. The reported plans remain uncertain, and no final decision on additional military action has been publicly confirmed.

The developments have intensified concerns surrounding the Strait of Hormuz, a critical shipping passage connecting major Persian Gulf oil producers with international markets. Disruptions to tanker traffic through the waterway have already constrained energy shipments, contributing to higher crude prices and increased volatility across commodity markets.

Recent attacks have added to the uncertainty. Iran-aligned Houthi forces launched strikes against targets in Saudi Arabia, including energy-related infrastructure, while additional incidents involving vessels in the Persian Gulf have heightened concerns about regional security.

The combination of military tensions and shipping disruptions has created a significant geopolitical risk premium in oil prices, with traders increasingly focused on the possibility of prolonged supply shortages.

Energy markets received additional support from U.S. inventory data released Wednesday. The Energy Information Administration reported that domestic crude inventories declined by approximately 3.1 million barrels during the previous week, exceeding analysts’ expectations for a smaller reduction.

The larger-than-expected drawdown suggests that available supplies remain tight, adding upward pressure to prices at a time when geopolitical developments are already limiting market confidence.

For investors, rising crude prices have implications extending well beyond the energy sector. Higher oil costs can increase gasoline and diesel prices, raise transportation expenses, and push up production costs for businesses across the economy.

Those pressures could complicate the Federal Reserve’s efforts to contain inflation. If energy prices remain elevated, policymakers may face additional challenges in determining when borrowing costs can move lower without reigniting broader price pressures.

The developments are particularly relevant for smaller companies, which may have less flexibility to absorb higher operating expenses or secure financing during periods of elevated interest rates.

At the same time, stronger oil prices can create opportunities for energy producers. Companies operating in North American oil and natural gas markets may benefit from improved commodity pricing, although production costs, hedging arrangements, and individual operating conditions influence their financial performance.

Among companies followed by Noble Capital Markets, InPlay Oil Corp. (TSX: IPO) operates in the Canadian oil and natural gas sector, while Alliance Resource Partners (NASDAQ: ARLP) maintains significant exposure to domestic energy markets through its coal operations and related interests. Their businesses illustrate different areas of the energy industry that investors may evaluate as commodity markets respond to geopolitical developments.

However, higher energy prices are not universally positive for the sector. Companies dependent on fuel-intensive transportation, manufacturing, and logistics may experience additional margin pressure if elevated prices persist.

The coming weeks could prove important for global oil markets as investors monitor diplomatic negotiations, military developments, and the outlook for energy shipments through the Persian Gulf.

For now, the combination of geopolitical uncertainty and tightening inventories suggests that oil prices could remain volatile, with significant implications for inflation, corporate earnings, and financial markets heading into the final months of 2026.

Release – Kodiak Commences Additional Metallurgical Testing Focused on Flowsheet Development & Optimization

Posted on by [email protected]

October 22, 2026 – Vancouver, British Columbia – Kodiak Copper Corp. (the “Company” or “Kodiak”) (TSX-V: KDK, OTCQX: KDKCF, Frankfurt: 5DD1) today reports that it has commenced an additional metallurgical testwork program, for its 100% owned MPD copper-gold porphyry project in southern British Columbia.

The testwork program will focus on flowsheet development and optimization and build on the test results received earlier this year (see news release here). It will include samples from all seven deposits that comprise the Mineral Resource Estimate at MPD: Gate, Ketchan, Man, Dillard, West, Adit and South (see Figure 1). Sample selection was designed to be representative of the mineralization, grade, lithology, and spatial variability across each deposit. Four composite samples representing the Southern Area (South, West and Adit), Northern Area (Man and Dillard), Ketchan and Gate will be tested. Testing will include mineralogy, comminution, gravity testwork for gold, flotation rougher and cleaner optimization, locked cycle testing and concentrate quality assessment. The results from the program are expected in Q1 2027.

Claudia Tornquist, President and CEO of Kodiak said,

“As we continue to grow the mineral resource at MPD through exploration, we are also advancing our metallurgical testwork to further de-risk the project and strengthen the foundation for future economic studies. Our metallurgical results to date are very encouraging, and this next phase of work is designed to expand on those positive findings. The program will focus on optimizing metal recoveries, particularly for gold, and produce valuable information on rock properties and hardness. Together with our ongoing exploration program and planned resource update in early 2027, this work represents another important step in unlocking the value of MPD for our shareholders.”

Kodiak has engaged Fuse Advisors Inc., Part of SLR (“Fuse”) to design and manage this metallurgical testwork program, with technical guidance from Kodiak advisor Mike Westendorf. Fuse is a mining consultancy with extensive experience across a wide range of deposit types and metals, including many porphyry copper projects in British Columbia. The laboratory work will be conducted in Parksville at Blue Coast Research Ltd (“Blue Coast”) under the supervision of Fuse Metallurgist Renee Goold, P.Eng, an independent Qualified Person as defined by National Instrument 43-101. Blue Coast is a leading provider of metallurgical testing services for the global mining industry.

Ms Goold has reviewed this news release and approved the technical information pertaining to the metallurgical work. Dave Skelton, P.Geol, Vice President Exploration and a Qualified Person as defined by National Instrument 43-101, has reviewed, and approved the technical information contained in this release.

On behalf of the Board of Directors

Kodiak Copper Corp.
 
Claudia Tornquist
President & CEO

For further information contact:
Nancy Curry, VP Corporate Development
[email protected]
+1 (604) 646-8362

Release – T3 Defense Delivers Mobile UAV Command-and-Control Vehicle to Israeli HLS Operator

Posted on by [email protected]

October 22, 2026 09:00 ET

NEW YORK and NETANYA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense businesses, today announced that its wholly owned subsidiary, Rimon Agencies Ltd. (“Rimon”), has delivered a drone-integrated mobile command-and-control (C2) vehicle to B.K. Vision Ltd. (“B.K. Vision”), a leading Israeli provider of homeland security (HLS) services. This delivery marks the transition from product introduction to customer deployment, representing the first unit delivered to a customer under the mobile unmanned aerial vehicle (UAV) and counter-UAV (C-UAV) platform line introduced by Rimon in August 2026.

Built by Rimon’s UAV Platforms project division, the fully integrated platform provides B.K. Vision with a self-contained base from which to launch, control and recover a UAV and manage a response where no fixed infrastructure exists.

“A command-and-control vehicle is central to a cohesive operation where power, communications, aircraft and operators all come together,” said Itamar Shimoni, Chief Executive Officer of Rimon. “We delivered B.K. Vision a vehicle that is ready to operate the day it arrives, bringing these capabilities together in a single mobile platform. As we continue to see an increasing need across defense and homeland security organizations in Israel and abroad, our focus is on applying Rimon’s engineering and integration capabilities to the operational requirements of additional defense and homeland security customers.”

“In August we said the drone threat had moved faster than the infrastructure built to answer it,” said Menny Shalom, Chairman and Chief Executive Officer of T3 Defense. “This delivery is that infrastructure, built and deployed. As the first command-and-control vehicle shipped under Rimon’s new platform line, it marks the transition from product introduction to customer delivery. Our focus is on translating this milestone into additional orders and building a repeatable business around mission-ready products.”

About Rimon

Rimon is a bespoke engineering and systems integration company that develops mission-ready infrastructure platforms for defense, homeland security, and emergency response operations. The company imports, distributes, and upgrades mobile power systems, elevated sensor masts, and builds integrated mission vehicles that support surveillance, communications, and command systems operating in environments where permanent infrastructure is unavailable. By engineering systems around real operational requirements, Rimon enables critical technologies to be deployed rapidly and operate reliably in demanding field conditions.

About T3 Defense Inc.

T3 Defense Inc. (Nasdaq: DFNS) is a defense company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with strong customer relationships and solid order backlogs, often capacity- and resource-constrained, in specialized areas such as drones and autonomous vehicles, counter-drone systems, advanced manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and strategy, and decentralized day-to-day operations, T3 Defense aims to strengthen essential defense capabilities and build long-term value. For more information, visit www.t3dfns.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the anticipated capabilities, configurations and availability of the command-and-control vehicles and trailers described herein; expected demand from defense and homeland security customers; the potential for additional orders or recurring revenue; and the Company’s growth strategy. These statements are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially, including the risk that a single delivery is not indicative of future orders; the absence of orders for the configurable platforms described herein; customer qualification, procurement timing and program funding; dependence on a limited number of customers; manufacturing execution, capacity and supply-chain risks; competitive and geopolitical conditions, including conditions in Israel; the Company’s liquidity and capital resources; the Company’s ability to maintain compliance with Nasdaq listing requirements; the integration of acquired businesses; and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contact Us:

T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

Rimon
Chen Ganzer
[email protected]

Investor Relations
The Equity Group Inc.
Lena Cati
[email protected]
+1 212 836-9611

Val Ferraro
[email protected]
+1 212 836-9633

Unicycive Therapeutics (UNCY) – NDA Resubmission Accepted For FDA Review

Posted on by [email protected]


Thursday, October 22, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

OLC Resubmission Given March 25, 2027 PDUFA Date. Unicycive announced that the FDA has accepted its NDA (New Drug Application) resubmission for OLC (oxylanthanum carbonate) for review. This follows the 30-day period after resubmission in which the FDA determined that it was sufficiently complete for review. The application received a PDUFA (Prescription Drug User Fee Act) date of March 25, 2027. This is the date the FDA must respond to the application by statute and aligns with the TDAPA program deadlines.

The NDA Contains Data From A New Manufacturing Partner. As we had expected, the resubmission was classified as Class 2 and received a six-month review. The CMC (Chemistry, Manufacturing, and Controls) section includes product manufacturing data from a new third-party manufacturing partner. The FDA inspected this manufacturer’s plant in March 2024 and gave a “No Action Indicated” status, the equivalent of a passing grade.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Proof of Concept

Posted on by [email protected]


Thursday, October 22, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Proof. It didn’t take long for SKYX Platforms and new subsidiary Deako to supply proof of concept on one of the key elements of the merger: i.e., cross-selling. Yesterday, SKYX announced that it will supply over 80,000 units of its advanced technologies to over 1,000 homes for Maronda Homes. We believe this announcement will be the first of many.

Details. The Company expects to deliver over 80,000 units of its advanced plug-and-play and smart home technologies to over 1,000 Maronda Homes residences in several states, including Ohio, Georgia, Maryland, and Pennsylvania. If the contract is similar to the $50/unit revenue previously disclosed, the contract would represent some $4 million in revenue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.